EZH2 alterations in follicular lymphoma: Biological and clinical correlations

Blood Cancer Journal

Volumn 7, Issue 4, 2017, Pages

  Huet, S ^a,b   Xerri, L ^c   Tesson, B ^d   Mareschal, S ^e   Taix, S ^c   Mescam Mancini, L ^c   Sohier, E ^f   Carrere M ^f   Lazarovici, J ^g   Casasnovas, O ^h   Tonon, L ^f   Boyault, S ^f   Hayette, S ^a,b   Haioun, C ⁱ   Fabiani, B ^j   Viari, A ^f   Jardin, F ^e   Salles, G ^b  

^a HOSPICES CIVILS DE LYON   (France)

^b CENTRE HOSPITALIER LYON SUD   (France)

^c AIX MARSEILLE UNIVERSITY   (France)

^d Institut Carnot CALYM   (France)

^e UNIVERSITÉ DE ROUEN   (France)

^f CENTRE LÉON BÉRARD   (France)

^g INSTITUT GUSTAVE ROUSSY   (France)

^h HÔPITAL DU BOCAGE   (France)

ⁱ HENRI MONDOR HOSPITAL   (France)

^j HÔPITAL SAINT ANTOINE   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

RITUXIMAB; TRANSCRIPTION FACTOR EZH2; EZH2 PROTEIN, HUMAN; HISTONE LYSINE METHYLTRANSFERASE; HISTONE METHYLTRANSFERASE;

ADULT; ARTICLE; CELL PROLIFERATION; CHROMOSOME 7; CODON; COHORT ANALYSIS; CONTROLLED STUDY; COPY NUMBER VARIATION; FEMALE; FOLLICULAR LYMPHOMA; FOLLOW UP; GENE EXPRESSION; GENE MUTATION; HISTONE METHYLATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RNA SEQUENCE; SANGER SEQUENCING; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION; TREATMENT OUTCOME; TUMOR BIOPSY; AGED; DISEASE FREE SURVIVAL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METHYLATION; MIDDLE AGED; MUTATION; PATHOLOGY; SEQUENCE ANALYSIS; TUMOR CELL LINE;

ADULT; AGED; CELL LINE, TUMOR; DISEASE-FREE SURVIVAL; ENHANCER OF ZESTE HOMOLOG 2 PROTEIN; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE-LYSINE N-METHYLTRANSFERASE; HUMANS; LYMPHOMA, FOLLICULAR; MALE; METHYLATION; MIDDLE AGED; MUTATION; POLYMORPHISM, SINGLE NUCLEOTIDE; SEQUENCE ANALYSIS, RNA;

EID: 85030033211     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/bcj.2017.32     Document Type: Article

References (37)

1. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC: Lyon, France, 2008.
2. Bachy E, Houot R, Morschhauser F, Sonet A, Brice P, Belhadj K et al. Long-term follow up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphoma. Haematologica 2013; 98: 1107-1114.
3. Morin RD, Johnson NA, Severson TM, Mungall AJ, An J, Goya R et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet 2010; 42: 181-185.
4. Pasqualucci L, Dominguez-Sola D, Chiarenza A, Fabbri G, Grunn A, Trifonov V et al. Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature 2011; 471: 189-195.
5. Pastore A, Jurinovic V, Kridel R, Hoster E, Staiger AM, Szczepanowski M et al. Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. Lancet Oncol 2015; 16: 1111-1122.
6. Viré E, Brenner C, Deplus R, Blanchon L, Fraga M, Didelot C et al. The Polycomb group protein EZH2 directly controls DNA methylation. Nature 2006; 439: 871-874.
7. Cao R, Wang L, Wang H, Xia L, Erdjument-Bromage H, Tempst P et al. Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science 2002; 298: 1039-1043.
8. Margueron R, Reinberg D. The polycomb complex PRC2 and its mark in life. Nature 2011; 469: 343-349.
9. Okosun J, Bödör C, Wang J, Araf S, Yang C-Y, Pan C et al. Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma. Nat Genet 2014; 46: 176-181.
10. 10 Bödör C, Grossmann V, Popov N, Okosun J, O'Riain C, Tan K et al. EZH2 mutations are frequent and represent an early event in follicular lymphoma. Blood 2013; 122: 3165-3168.
11. Sneeringer CJ, Scott MP, Kuntz KW, Knutson SK, Pollock RM, Richon VM et al. Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lym-phomas. Proc Natl Acad Sci USA 2010; 107: 20980-20985.
12. Yap DB, Chu J, Berg T, Schapira M, Cheng S-WG, Moradian A et al. Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation. Blood 2011; 117: 2451-2459.
13. McCabe MT, Ott HM, Ganji G, Korenchuk S, Thompson C, Van Aller GS et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 2012; 492: 108-112.
14. Béguelin W, Popovic R, Teater M, Jiang Y, Bunting KL, Rosen M et al. EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. Cancer Cell 2013; 23: 677-692.
15. Souroullas GP, Jeck WR, Parker JS, Simon JM, Liu J-Y, Paulk J et al. An oncogenic Ezh2 mutation induces tumors through global redistribution of histone 3 lysine 27 trimethylation. Nat Med 2016; 22: 632-640.
16. Caganova M, Carrisi C, Varano G, Mainoldi F, Zanardi F, Germain P-L et al. Germinal center dysregulation by histone methyltransferase EZH2 promotes lymphomagenesis. J Clin Invest 2013; 123: 5009-5022.
17. Knutson SK, Kawano S, Minoshima Y, Warholic NM, Huang K-C, Xiao Y et al. Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma. Mol Cancer Ther 2014; 13: 842-854.
18. Qi W, Chan H, Teng L, Li L, Chuai S, Zhang R et al. Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation. Proc Natl Acad Sci USA 2012; 109: 21360-21365.
19. Dubois S, Mareschal S, Picquenot J-M, Viailly P-J, Bohers E, Cornic M et al. Immunohistochemical and genomic profiles of diffuse large B-cell lymphomas: implications for targeted EZH2 inhibitor therapy? Oncotarget 2015; 6: 16712-16724.
20. Zhou Z, Gao J, Popovic R, Wolniak K, Parimi V, Winter JN et al. Strong expression of EZH2 and accumulation of trimethylated H3K27 in diffuse large B-cell lymphoma independent of cell of origin and EZH2 codon 641 mutation. Leuk Lymphoma 2015; 56: 2895-2901.
21. Horsman DE, Connors JM, Pantzar T, Gascoyne RD. Analysis of secondary chromosomal alterations in 165 cases of follicular lymphoma with t(14;18). Genes Chromosomes Cancer 2001; 30: 375-382.
22. Bouska A, McKeithan TW, Deffenbacher KE, Lachel C, Wright GW, Iqbal J et al. Genome-wide copy-number analyses reveal genomic abnormalities involved in transformation of follicular lymphoma. Blood 2014; 123: 1681-1690.
23. Salles G, Seymour JF, Offner F, López-Guillermo A, Belada D, Xerri L et al. Ritux-imab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 2011; 377: 42-51.
24. Kim D, Pertea G, Trapnell C, Pimentel H, Kelley R, Salzberg SL. TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biol 2013; 14: R36.
25. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res 2010; 20: 1297-1303.
26. Anders S, Pyl PT, Huber W. HTSeq-a Python framework to work with high-throughput sequencing data. Bioinformatics 2015; 31: 166-169.
27. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol 2014; 15: 550.
28. Popova T, Manié E, Stoppa-Lyonnet D, Rigaill G, Barillot E, Stern MH. Genome Alteration Print (GAP): a tool to visualize and mine complex cancer genomic profiles obtained by SNP arrays. Genome Biol 2009; 10: R128.
29. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B 1995; 57: 289-300.
30. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005; 102: 15545-15550.
31. Casulo C, Byrtek M, Dawson KL, Zhou X, Farber CM, Flowers CR et al. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study. J Clin Oncol 2015; 33: 2516-2522.
32. Maurer MJ, Bachy E, Ghesquières H, Ansell SM, Nowakowski GS, Thompson CA et al. Early event status informs subsequent outcome in newly diagnosed folli-cular lymphoma. Am J Hematol 2016; 91: 1096-1101.
33. Velichutina I, Shaknovich R, Geng H, Johnson NA, Gascoyne RD, Melnick AM et al. EZH2-mediated epigenetic silencing in germinal center B cells contributes to proliferation and lymphomagenesis. Blood 2010; 116: 5247-5255.
34. Louissaint A, Schafernak KT, Geyer JT, Kovach AE, Ghandi M, Gratzinger D et al. Pediatric-type nodal follicular lymphoma: a biologically distinct lymphoma with frequent MAPK pathway mutations. Blood 2016; 128: 1093-1100.
35. Schmidt J, Gong S, Marafioti T, Mankel B, Gonzalez-Farre B, Balagué O et al. Genome-wide analysis of pediatric-type follicular lymphoma reveals low genetic complexity and recurrent alterations of TNFRSF14 gene. Blood 2016; 128: 1101-1111.
36. Jurinovic V, Kridel R, Staiger AM, Szczepanowski M, Horn H, Dreyling MH et al. Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy. Blood 2016; 128: 1112-1120.
37. Sarkozy C, Seymour JF, Ferme C, Caballero D, Ghesquieres H, Leppa S et al. Ritux-imab maintenance obviates the poor prognosis associated with circulating lym-phoma cells in patients with follicular lymphoma. Blood 2014; 123: 2740-2742.